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Abstract 
Background: Pancreatic cancer is one of the most lethal of human malignancies known to date and shows rela-
tive insensitivity towards most of the clinically available therapy regimens. 3,5-bis(2-fluorobenzylidene)-4-piperidone 
(EF24), a novel synthetic curcumin analog, has shown promising in vitro therapeutic efficacy in various human cancer 
cells, but insufficient water solubility and systemic bioavailability limit its clinical application. Here, we describe nano-
encapsulation of EF24 into pegylated liposomes (Lipo-EF24) and evaluation of these particles in preclinical in vitro 
and in vivo model systems of pancreatic cancer.
Results: Transmission electron microscopy and size distribution studies by dynamic light scattering confirmed intact 
spherical morphology of the formed liposomes with an average diameter of less than 150 nm. In vitro, treatment with 
Lipo-EF24 induced growth inhibition and apoptosis in MIAPaCa and Pa03C pancreatic cancer cells as assessed by 
using cell viability and proliferation assays, replating and soft agar clonogenicity assays as well as western blot analy-
ses. Lipo-EF24 potently suppressed NF-kappaB nuclear translocation by inhibiting phosphorylation and subsequent 
degradation of its inhibitor I-kappa-B-alpha. In vivo, synergistic tumor growth inhibition was observed in MIAPaCa 
xenografts when Lipo-EF24 was given in combination with the standard-of-care cytotoxic agent gemcitabine. In line 
with in vitro observations, western blot analysis revealed decreased phosphorylation of I-kappa-B-alpha in excised 
Lipo-EF24-treated xenograft tumor tissues.
Conclusion: Due to its promising therapeutic efficacy and favorable toxicity profile Lipo-EF24 might be a promising 
starting point for development of future combinatorial therapeutic regimens against pancreatic cancer.
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Background
Ductal adenocarcinoma of the pancreas (also referred 
to as ‘pancreatic cancer’ throughout the following text) 
remains one of the most dismal of human malignancies to 
date and accounts for an estimated over 200,000 fatalities 
every year. Its 5 year overall survival rate of less that 5 % 
reflects the gloomy prognosis of this disease and is at 
least in part due to its astonishing resistance to therapeu-
tic intervention [1]. Moreover, as opposed to most other 
cancer types incident rates are rising and pancreatic can-
cer has been predicted to become the second most com-
mon cause of cancer-related death in the United States 
within the next decade [2]. Currently available chemo-
therapeutic regimens that represent the only therapeutic 
option for the vast majority of locally advanced or meta-
static disease states show moderate efficacy and usually 
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extend median overall survival rates by only few weeks 
[3]. Therefore, the development and rapid, thorough pre-
clinical evaluation of novel therapeutic strategies against 
pancreatic cancer represents an urgent clinical need.
The plant alkaloid curcumin has long been known 
in traditional ayurvedic medicine and has recently 
been shown to exhibit promising antineoplastic activ-
ity in pancreatic cancer in  vitro and in  vivo model sys-
tems by our own group as well as by others [4–7]. The 
synthetic curcumin monoketone derivative 3,5-bis(2-
fluorobenzylidene)-4-piperidone (EF24) shows potent 
in  vitro anticancer activity [8], however, similar to the 
parent compound curcumin, further clinical develop-
ment into a suitable drug candidate is hampered by its 
poor water solubility and bioavailability.
To overcome these difficulties, this study reports crea-
tion and preclinical evaluation of a liposomal nano-
formulation of EF24 (Lipo-EF24). Liposomal drug 
encapsulation is now well established, and in fact lipo-
somal nanoformulations of cytotoxic chemotherapeutics 
are routinely used in clinical oncology by now. A promi-
nent example is the use of liposomal doxorubicin formu-
lations (e.g. Caelyx, Myocet) instead of free drug, which 
showed enhanced therapeutic efficacy and considerably 
better toxicity profiles, particularly far lesser cardiotoxic-
ity [9, 10]. Therefore, further translational development 
of Lipo-EF24 as presented here into clinical evaluation 
appears to be feasible in principle.
The liposomal nanoformulation of EF24 generated here 
(designated “Lipo-EF24”) showed potent in  vitro and 
in  vivo antineoplastic activity in clinically relevant pan-
creatic cancer models. Moreover, a very favorable toxicity 
profile was observed, rendering Lipo-EF24 a promising 
candidate for further development and a potential part-





nolamine-N-[poly(ethylene glycol)-2000] (PEG-DSPE) 
were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). Cholesterol, EF24 (>99  % purity) and curcumin 
were purchased from Sigma-Aldrich (Steinheim, Ger-
many). Gemcitabine was obtained from NetQem LLC 
(Durham, NC, USA) and dissolved in sterile NaCl solu-
tion (0.9 % w/v) on the day of use.
Synthesis of void and EF24‑loaded liposomes
Liposomes were prepared using the film hydration 
method. Briefly, PEG-stabilized void liposomes were pre-
pared by a mixture of POPC, cholesterol, and PEG-DSPE, 
at a molar ratio of 65:30:5  mol%. EF24 containing 
liposomes were produced at molar ratio of 60  mol% 
POPC, 30  mol% Cholesterol, 5  mol% PEG-DSPE, and 
5  mol% EF24. Unilamellar liposomes were obtained by 
extruding multilamellar vesicles through polycarbon-
ate membranes as previously described [11]. Briefly, 
the mixture of phospholipids and EF24 in chloroform, 
respectively, was dried in a rotary evaporator under 
reduced pressure. The resulted lipid film was hydrated 
with phosphate buffered saline (PBS) to reach a final lipid 
concentration of 50 µmol/mL. The multilamellar vesicles, 
obtained by thoroughly mixing the aqueous solutions of 
lipids, were extruded five times through a 200  nm and 
five times through a 100  nm polycarbonate membrane 
(Isopore™, Millipore, Schwalbach, Germany) at 65  °C 
using a Lipex™ 10  mL Thermobarrel Extruder (Lipex™ 
Biomembranes, Inc., Vancouver, Canada). EF24 excess 
was removed by gel permeation chromatography (Sepha-
dex G-50®; Sigma-Aldrich, Steinheim, Germany). Phos-
pholipid concentration was quantified with a standard 
phosphate assay [12–14].
Incorporation of EF24 in liposomes was determined by 
gas chromatography–mass spectrometry (Hewlett Pack-
ard 5890, Series II, Quadrupol MS, column CP-Sil m8, 
50 m, 0.25 µm × 0.25 mm, Böblingen, Germany).
Dynamic light scattering (DLS) measurements
The average size and the size distribution of the formed 
liposomes were measured using a Zetatrac system 
(Microtrac Europe GmbH, Meerbusch, Germany). Briefly 
before the measurements, the liposomes were diluted in 
PBS and filtered through Millipore filters with an average 
pore size of 0.22 µm. The measurements were performed 
at room temperature and at a scattering angle of 180°. All 
measurements were done in triplicates and mean sizes 
were calculated.
Transmission electron microscopy (TEM)
TEM pictures of void and EF24-loaded liposomes were 
acquired using a Leo 912 OMEGA instrument (Carl 
Zeiss, Oberkochen, Germany) operating at 120  kV. 
Briefly, a drop of diluted solution of liposomes was coated 
on carbon-coated copper grids (Quantifoil Micro Tools 
GmbH, Jena, Germany) and was then immediately shock-
frozen in liquid ethane before loading in the microscope. 
For each probe three grids were prepared and all digital 
images were captured at a magnification of 6–12K using 
a Proscan HSC 2 camera [15].
Cell culture
Human pancreatic cancer cell lines were cultured in 
Dulbecco’s Modified Eagles Medium (DMEM, PAA 
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Laboratories, Pasching, Austria) supplemented with 10 % 
FBS, 0.1 mM non-essential amino acids solution, 1 mM 
sodium pyruvate, and 1  % penicillin/streptomycin (all 
PAA Laboratories, Pasching, Austria) as well as 5 μg/mL 
plasmocin (InvivoGen, San Diego, CA). Immortalized 
non-malignant human pancreatic epithelial cells (hTERT-
HPNE) were cultured as described elsewhere [16, 17]. All 
cell lines were grown in a humidified atmosphere at 37 °C 
in the presence of 5 % CO2 and were regularly checked 
for mycoplasma infection using a PCR based assay as 
previously described [18].
Cell viability assays
Cell viability was determined using 3-(4,5-dimethyl-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assays as previously described [4, 
19]. Briefly, 2000 cells per well were plated in full growth 
media and treated with either free EF24 or liposome-
encapsulated EF24 for 72  h, respectively. At 72  h, the 
assay was terminated and relative growth inhibition com-
pared to mock treated cells was determined using CellTi-
ter 96 reagent (Promega, Madison, WI), as described in 
the manufacturer’s protocol. All experiments were set up 
in triplicates.
Proliferation assay (cell trace violet dye staining)
Cell proliferation was measured in  vitro using Cell 
Trace Violet Cell Proliferation Kit (ThermoFisher Scien-
tific GmBH, Schwerte, Germany). In brief, 1 × 106 cells 
were labeled with a vital dye cell trace violet (5 µmol/L) 
according to manufacturer’s protocol, seeded in 12 well 
plates and later treated with void liposomes as well as 
EF24 loaded liposomes at 5 and 10 µM respectively. After 
48 h of treatment, cells were harvested, washed and ana-
lyzed for violet dye fluorescence using flow cytometry.
Clonogenicity assays
Cells were seeded in six-well plates at a density of 1000 
cells per well in the presence of different concentra-
tions of void or EF24-containing liposomes, respectively. 
After 24  h, medium containing liposomal solutions was 
replaced with normal medium and colonies were allowed 
to grow. Once colonies became visible, cells were fixed 
and stained using 0.05  % crystal violet (Sigma Aldrich, 
Steinheim, Germany). Colonies were counted and colony 
counts were normalized to the mean colony count of void 
liposome-treated cells.
Anchorage independent growth assays
Soft agar assays were set up in six well plates as described 
previously [17]. In brief, a base agar layer was formed by 
mixing 2 mL of media and 1 % agarose containing differ-
ent concentrations of either void liposomes or liposomes 
encapsulating EF24, respectively. Next, on top of it a sec-
ond layer of 2  mL media containing 0.7  % agarose and 
10,000 cells were poured in the presence of void or EF24-
loaded liposomes and allowed to solidify. Finally, 2  mL 
of media was added on top of the agarose layers and the 
plates were incubated at 37 °C for 2 weeks. After 2 weeks, 
the visible colonies were stained and visualized using 
trans-UV illumination (BioRad, Hercules, CA). Colonies 
were counted and colony counts were normalized to the 
mean colony count of the respective void liposomes con-
trols. All assays were set up in triplicates.
Western blot analyses
Cells were lysed using radioimmunoprecipitation assay 
buffer (RIPA: 1  % IgepalCA630, 0.5  % sodium deoxy-
cholate, 0.1  % SDS, 2  mM EDTA) supplemented with 
protease and phosphatase inhibitor cocktails (Sigma 
Aldrich, Steinheim, Germany). 50  µg of total pro-
tein was separated on 4–12  % Nupage bis–tris gels 
(Life Technologies, Darmstadt, Germany) and trans-
ferred onto PVDF membranes (Millipore, Billerica, 
MA, USA). The blots were blocked using either 5  % 
(w/v) BSA or 5 % (w/v) milk in TBST for 1 h and then 
probed using primary antibodies against the p65 subu-
nit of Nuclear Factor kappaB (NF-kappaB), Inhibitory 
Protein I-kappa-B-alpha, Caspase-3, PARP or GAPDH 
(1:1000, Cell Signaling, Danvers, MA) as well as HRP-
coupled secondary antibodies directed against rab-
bit or mouse IgG, respectively (1:2000; Cell Signaling, 
Danvers, MA). Detection was performed as previously 
described [20]. Cytoplasmic and nuclear proteins were 
extracted using the NE-PER nuclear and cytoplasmic 
extraction kit (Thermo-Fischer Scientific, Schwerte, 
Germany).
Ex vivo red blood cell (RBC) hemolysis assay
Fresh mouse blood was collected (n  =  6) and the red 
blood cells (RBCs) were separated from the serum by 
centrifugation. The collected blood cells were then 
washed twice with PBS and resuspended in PBS (pH 7.4). 
The RBC suspension (2 % v/v) was then incubated with 
varying concentrations of void or EF24-loaded liposomes 
at 37  °C for 1  h. After incubation, the supernatant was 
centrifuged at 500×g for 5 min and subjected to measure-
ment for hemoglobin release by microplate reader (FLU-
Ostar Optima, BMG Labtech, Offenburg, Germany) at 
450 nm. Samples incubated with 1 % Triton X-100 served 
as positive controls (100  % hemolysis), addition of PBS 
served as negative controls (0 % hemolysis), respectively.
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Sample preparation for LC–MS/MS measurements
LC–MS/MS samples were prepared by adding 4  µL of 
serum to a mixture of 96  µL methanol, 96  µL H2O and 
4  µL of ISTD stock solution (=1  mg/L ISTD in metha-
nol). After thorough mixing, samples were transferred 
into MS vials and stored in the sample manager at 10 °C. 
All solvents were of LCMS grade.
Pharmacokinetic analysis of EF24 loaded Liposomes using 
LC–MS/MS
For pharmacokinetic analyses, a cohort of 24 mice were 
administered a single dose of liposomal EF24 (10 mg/kg) 
intravenously through tail vein. Serum samples (2–4 mice 
per time point) were collected at 0.25, 1, 2, 3, 4, 6, 8 and 
24 h and stored at −80 °C prior to and after use. LC–MS/
MS analyses were carried out on a Waters Xevo TQ-S 
Triple-quad system equipped with a Waters Acquity 
I-Class UPLC system, an FTN sample manager, binary 
solvent manager and TUV detector. A Waters Acquity 
UPLC BEH C18 column (130 Å, 1.7 µm, 2.1 × 100 mm) 
together with a Waters Acquity UPLC BEH C18 Van-
Guard pre-column (130  Å, 1.7  µm, 2.1  ×  5  mm) was 
used for separation. Data recording was achieved with 
the MassLynx 4.1 software package, data processing and 
quantification was performed with the integrated Tar-
getLynx software using a quadratic regression model. 
Detailed LC–MS/MS methodology and data quantifica-
tion is provided as Additional file 1.
Generation of xenografts and drug treatment
Animal experiments described comply with Directive 
2010/63/EU and were approved by the government of 
the state of North Rhine-Westphalia (AZ84-02.04.2011.
A138). Mice were maintained according to the guidelines 
of the Federation of European Laboratory Animal Sci-
ence Associations (FELASA). Subcutaneous xenografts 
were generated by injecting 1 × 106 MIAPaCa cells sus-
pended in a total volume of 200  µL [PBS/Matrigel (BD 
Biosciences), 1:1 (v/v), prechilled to 4 °C] into 5–6 weeks 
old athymic nu/nu mice (Jackson Laboratory, Maine, 
USA). After 2 weeks, subcutaneous tumor volumes were 
measured using digital calipers (Milomex, Pulloxhill, UK) 
and calculated using the formula V =  1/2(ab2), where a 
is the longest and b is the shortest orthogonal tumor 
diameter [21]. Mice were then randomized and divided 
into four cohorts of eight animals each and adminis-
tered one of the following regimens: (a) void liposomes, 
(b) EF24 loaded in liposomes at a dose of 10  mg/kg i.v. 
on alternate days, (c) gemcitabine at a dose of 20  mg/
kg i.p. twice weekly, or (d) combination of EF24-loaded 
liposomes and gemcitabine. Tumor volumes and body 
weights were measured once weekly. After 3  weeks, 
tumors and visceral organs were harvested and preserved 
in 10 % neutral buffered formalin or snap-frozen for fur-
ther analyses.
Statistical analysis
Two-tailed Student’s t test and Mann–Whitney U test 
were performed using Graph Pad Prism for Windows 
version 6. Kruskal–Wallis analyses were done using SPSS 
for Microsoft Windows. p < 0.05 was regarded as statis-
tically significant. Unless indicated otherwise, results are 
shown as mean ± SD. Further analyses are described in 
the Additional file 1.
Results
Synthetic analog of curcumin EF24 shows more potent 
growth inhibition in pancreatic cancer cell lines in vitro
The therapeutic activity of EF24 was tested and com-
pared to its parent compound curcumin in a panel of ten 
different pancreatic cancer cell lines using MTS assays 
(Fig.  1a, b). As shown in the figure, EF24 inhibited net 
cell growth of pancreatic cancer cells in a dose depend-
ent manner and with almost 10- to 20-fold lower IC50 as 
compared to curcumin across various cell lines. Moreo-
ver, EF24 also abrogated the ability of pancreatic cancer 
cells to form colonies at about 10-fold lower concentra-
tions than curcumin in two different cell lines, MiaPaCa 
and Pa03C, respectively (Fig. 1c). Thus, our results show 
enhanced antineoplastic activity of EF24 on pancreatic 
cancer cell lines as compared to curcumin, which is in 
line with previous studies in other cancers [22–24].
Synthesis and characterization of pegylated void 
and liposomal EF24
Hydration technique was used to generate liposomes in 
the presence of EF24, followed by an extrusion procedure 
to obtain a homogenous particle size. Due to its lipophilic 
structure, EF24 was predominantly encapsulated in the 
interior of liposomal bilayers. The average diameter and 
size distribution of void and EF24-loaded liposomes were 
routinely measured using dynamic light scattering (DLS) 
as illustrated in Fig.  2a. Both void liposomes as well as 
liposomes loaded with EF24 showed a narrow size dis-
tribution with an average diameter of less than 150 nm. 
Likewise, transmission electron microscopy (TEM) of the 
obtained liposomal particles demonstrated intact, round 
vesicles with an average diameter of <150  nm, and no 
difference in mean size was observed between void and 
EF24-loaded liposomes. Moreover, mixing of phospho-
lipids and EF24 at different ratios revealed a maximum 
encapsulation of 5  mol% of EF24 in liposomes without 
affecting the structural integrity of liposomes (Fig.  2b). 
Loading of EF24 in liposomes was determined using 
gel permeation chromatography and unencapsulated 
EF24 in the eluted buffer was quantified by means of 
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Fig. 1 Growth inhibition of pancreatic cancer cell lines by EF24 and by curcumin. A panel of ten pancreatic cancer cell lines was exposed to 
increasing doses of a curcumin or b EF24 for 72 h, and cell viability was determined using MTS assays. Across all cell lines, EF24 inhibited viability at 
approximately 10- to 20-fold lower IC50 as compared to curcumin. c Similar effects were observed in clonogenic assays, where EF24 abrogated the 
ability of pancreatic cancer cells to form colonies at concentrations that were about tenfold lower than the required curcumin doses (all experi-
ments were done in triplicates and repeated at least once; the figure shows pictures from two representative experiments)
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gas chromatography–mass spectrometry (GC–MS). No 
EF24 was detected in different eluates thereby confirming 
complete and stable incorporation of EF24 within liposo-
mal phospholipid bilayers. Next, liposomal particles thus 
prepared were tested for their stability and shelf life at 
different storage temperatures (4, 20, and 37  °C, respec-
tively) using DLS. Of note, liposomes displayed high sta-
bility and showed no agglomeration or change in their 
average diameter over 40  days (Fig.  2c), possibly due to 
PEGylation of the liposomal surface.
Pegylated liposomal EF24 (Lipo‑EF24) impairs growth 
and abrogates colony formation of pancreatic cancer cell 
lines in vitro
The therapeutic efficacy of liposomal EF24 was exam-
ined in two different human pancreatic cancer lines 
(MIAPaCa and Pa03C) and directly compared to free 
EF24 or void liposomes, respectively, using MTS assay. 
As shown in Fig.  3a, Lipo-EF24 significantly inhibited 
growth of both cell lines in a dose-dependent manner 
and to an extent that was comparable to that of free EF24 
while void liposomes showed negligible effects on cell 
growth. Moreover, when assessed using replating assays, 
both the cell lines mentioned above failed to grow colo-
nies from single cell suspensions in the presence of lipo-
somal EF24 but readily formed colonies when exposed 
to void liposomes (Fig.  3b). Likewise, liposomal EF24 
potently and reproducibly abrogated anchorage inde-
pendent growth of MIAPaCa and Pa03C cells in softagar, 
while such an effect was not observed for void liposomes 
or untreated controls (Fig.  3c). Next, the effect of lipo-
somal EF24 on cellular proliferation was analyzed using 
Fig. 2 Synthesis and characterization of void and EF24-containing PEGylated liposomes. Pegylated liposomes synthesized using a lipid hydration 
method were further characterized using DLS and TEM. a DLS of void and EF24-loaded liposomes revealed a narrow size distribution with an aver-
age diameter of less than 150 nm. b Transmission electron microscopy of void (left panel) and EF24-containing liposomes (right panel) demonstrated 
spherical morphology and an average diameter of around 120 nm, in line with the data obtained by DLS. c The stabilities of void and EF24-loaded 
liposomes were determined at three different temperatures (4, 20 and 37 °C) using DLS over a period of 40 days
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a CFSE dilution assay, which relies on the depletion of 
fluorescence intensity of CFSE with cell division. Of note, 
addition of Lipo-EF24 to culture media at concentrations 
of 5 or 10 µM on CFSE labeled cells for 48 h significantly 
decreased proliferation of both cell lines as compared to 
controls (Fig. 4a).
Lipo‑EF24 induces apoptosis in pancreatic cancer cells
Previous studies suggested that EF24 might induce apop-
tosis in various different cancers including ovarian, gas-
trointestinal and breast cancer [23, 25, 26]. Therefore, in 
order to test whether EF24 retains its biological activ-
ity despite being encapsulated into liposomal particles, 
MIAPaCa or Pa03C pancreatic cancer cells were treated 
with different concentrations of either void liposomes or 
Lipo-EF24 for 24 h and expression levels of cleaved poly 
(ADP-ribose) polymerase (cl. PARP) as well as caspase-3 
were determined by western blot analysis. As demon-
strated in Fig.  4b, Lipo-EF24 induced cleavage of PARP 
in both cell lines tested in a dose-dependent manner. 
Expression levels of caspase-3 were found to be reduced 
by Lipo-EF24 at higher concentrations of 10 µM in MIA-
PaCa, or at 5 and 10 µM in Pa03C cells, respectively. Void 
liposomes on the other hand did not alter expression pat-
terns in either of these cell lines.
Lipo‑EF24 suppresses NF‑kappaB activation by inhibiting 
phosphorylation and degradation of I‑kappa‑B‑alpha
The oncogenic NF-kappaB pathway is constitutively 
active in human pancreatic cancer [27], moreover cur-
cumin has previously been identified as potent inhibi-
tor of NF-kappaB signaling [28]. A recent study suggests 
that the curcumin derivative EF24 suppresses NF-kap-
paB activation by directly inhibiting the degradation of 
I-kappa-B-alpha [24], the inhibitory cytosolic subunit 
of NF-kappaB, whose phosphorylation and subsequent 
degradation is a prerequisite for activation of the NF-
kappaB pathway. Hence, in order to measure the effects 
Fig. 3 Lipo-EF24 inhibits growth and clonogenicity of pancreatic cancer cell lines. a MTS assays were performed using equivalent doses of free and 
liposomal EF24 in two different pancreatic cancer cell lines, MIAPaCa and Pa03C. In both cell lines, liposomal EF24 demonstrated marked growth 
suppression comparable to that of free drug. Further, liposomal EF24 caused significant, dose-dependent reduction in the ability of these cells to 
form colonies in replating assays (b) and inhibited anchorage-independent growth in soft agar (c). Void liposomes showed no significant effect in 
any of these cell lines. Representative images from one of three independent experiments are shown
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of Lipo-EF24 on NF-kappaB signaling, cytoplasmic and 
nuclear proteins were extracted from treated MIAPaCa 
and Pa03C cells, respectively, and subjected to western 
blot analysis. As shown in Fig.  5, liposomal EF24 effec-
tively inhibited phosphorylation of I-kappa-B-alpha as 
well as NF-kappaB-p65 and subsequent nuclear translo-
cation of NF-kappaB-p65 in a dose-dependent manner. 
Moreover, a marked increase in the expression levels of 
total I-kappa-B-alpha was also observed in MIAPaCa 
cells treated with Lipo-EF24 at a concentration of 10 µM, 
indicating that EF24 protects I-kappa-B-alpha from sub-
sequent cytosolic degradation.
Inertness of void liposomes in vitro and in vivo
Cytotoxicity of pegylated void liposomes was assessed 
in an extended panel of ten pancreatic cancer cell lines 
and one immortalized benign human pancreatic ductal 
epithelial cell line (HPNE). Void liposomes did not show 
any cytotoxic effect over a wide dose range from 43 µg/
mL up to 864  µg/mL (Fig.  6a). Next, ex  vivo hemoly-
sis assays were performed to check for possible adverse 
effects of liposomes on survival of red blood cells. For 
this, separated murine red blood cells were exposed to 
void or EF24-loaded liposomes, respectively, at concen-
trations ranging from 190 to 1900  µg/mL. Even at the 
highest concentrations tested (i.e. nearly 2  mg/mL), the 
hemolytic activity of void or EF24-loaded liposomes 
measured did not exceed 20  % as compared to positive 
control samples (100 % hemolysis) (Fig. 6b). To assess for 
in  vivo toxicity, void or EF24-loaded liposomes, respec-
tively, were administered to CD1 wildtype mice at a dose 
of 10  mg/kg by i.v. injection thrice weekly for 3  weeks, 
mock injections of PBS served as controls. Of note, mice 
treated with either void or drug-loaded liposomes did 
not show any signs of distress, body weight loss or any 
behavioral conspicuousness as compared to mock treated 
animals during the entire course of the experiment 
(Fig.  6c). Thorough necropsy and examination of major 
Fig. 4 Lipo-EF24 inhibits proliferation and induces apoptosis in pancreatic cancer cells. a CFSE staining assays were used to measure the effect of 
Lipo-EF24 on pancreatic cancer cell proliferation. CFSE-labeled MIAPaCa and Pa03C cells were treated with Lipo-EF24 at concentrations of 5 and 
10 µM or void liposomes for 48 h and then analysed using flow cytometry. Proliferation was indicated by a decrease of fluorescence intensity. b In 
order to determine apoptosis rates, MIAPaCa and Pa03C cells were treated with indicated concentrations of void liposomes or Lipo-EF24 for 24 h 
and protein expression levels of cleaved PARP or procaspase-3 were quantified from whole cell lysates by immunoblotting
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organs, including liver, lungs, kidney, spleen, pancreas, 
did not reveal any discernible gross or histomorphologi-
cal abnormalities (Fig. 6d).
In vivo pharmacokinetic analysis of Lipo‑EF24 using liquid 
chromatography–mass spectrometry (LC–MS/MS)
The mice were injected intravenously with a single dose 
of encapsulated EF24 (10  mg/kg) at t =  0  h. Peripheral 
blood samples drawn at different time intervals (0.25, 
1, 2, 3, 4, 6, 8 and 24 h, respectively) were quantified by 
means of LC–MS/MS and the results obtained were aver-
aged afterwards. The data thus acquired were plotted on 
a linear and semi-logarithmic scale (Fig.  7). As evident 
from these graphs, a rapid initial decrease in mean EF24 
plasma concentrations within the first hour was fol-
lowed by a subsequent phase of less pronounced decline 
between t = 1 h and t = 8 h. At 24 h, mean plasma lev-
els of EF24 were found to be below the detection limit. 
Thus, a distribution phase within the first hours and an 
elimination phase (after t = 1 h) could be differentiated. 
Both phases were fitted separately on a semi-logarithmic 
scale, which yielded rate constants of kdist = 4.25 h−1 and 
kelim  =  0.31  h−1, respectively. Corresponding half-life 
values were t1/2,dist = 0.16 h and t1/2,elim = 2.23 h. Due to 
sharp initial concentration decrease, the area under the 
concentration–time curve (AUC) was determined by 
both linear and logarithmic trapezoidal method, which 
yielded corresponding values of AUClin = 3074 ng h L−1 
and AUClog = 2456 ng h L−1, respectively. Upon extrap-
olation from t  =  0.25  h to t  =  0  h, values amount to 
AUClin,0 = 4197 ng h L−1 and AUClog,0 = 3573 ng h L−1, 
respectively. Additionally, extrapolating the concentra-
tion c to t = 0 h results in cmax = 5023 ng L−1 (Fig. 7a). 
For comparison, the pharmacokinetic profile of pure 
EF24 solubilized in DMSO was also determined by 
LC–MS/MS in the time regime between 0.25 and 8  h 
after intravenous injection of a single dose of EF24 
(10 mg kg−1). Without the liposomic encapsulation EF24 
shows no sign of a distribution phase, but is constantly 
eliminated with a rate constant of 0.4683 h−1 and a half-
life of t1/2  =  2.14  h. The measured peak concentration 
at t =  0.25 h is roughly 75 % of the peak concentration 
of encapsulated EF24. Extrapolating the first three con-
centration time points to t = 0 yields an initial concen-
tration of roughly 5500  ng  L−1, which is slightly higher 
than in the case of EF24 encapsulated in liposomes. 
Accordingly, the AUC also amounts to a higher value of 
5258 ng L−1 h−1 (Fig. 7b).
Lipo‑EF24 shows synergistic in vivo growth inhibition 
in combination with gemcitabine in pancreatic cancer 
xenografts
In vivo therapeutic efficacy of Lipo-EF24—administered 
as monotherapy as well as in combination with the stand-
ard-of-care cytostatic drug gemcitabine—was assessed 
using MIAPaCa pancreatic cancer xenografts. In line 
with previous reports gemcitabine caused significant 
growth retardation of MIAPaCa xenografts. As opposed 
to this, monotherapy with Lipo-EF24 lead to only mar-
ginal initial growth delay during the first 2  weeks of 
therapy (data not shown), but this effect did not per-
sist during the following course of therapy, possibly due 
to in  vivo selection of resistant subclones of neoplastic 
cells under monotherapy. This observation prompted 
investigation of a combinatorial regimen of Lipo-EF24 
plus gemcitabine. Of note, significantly enhanced tumor 
growth inhibition was observed in mice that received a 
combination regimen of Lipo-EF24 plus gemcitabine as 
Fig. 5 Lipo-EF24 blocks I-kappa-B-alpha (IkBa) phosphorylation and NF-kappaB activation. The effect of void liposomes (VL) or Lipo-EF24 (EL) 
on NF-kappaB pathway activity in a MIAPaCa or b Pa03C cells was assessed by quantifying the protein expression levels of phospho-I-kappa-B-
alpha (p-IκBα), I-kappa-B-alpha (IκBα), phospho-NF-kappaB-p65 (p-NFκB p65) and NF-kappaBp-65 (NFκB p65) in cytoplasmic (CE) as well as nuclear 
(NE) extracts, GAPDH was used as loading control
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compared to single agent gemcitabine or Lipo-EF24 ther-
apy, respectively (Fig.  8a). Likewise, significant decrease 
in the average final tumor weights was observed in the 
combination therapy as compared to the other three 
treatment arms (Fig.  8b). Thorough necropsy and his-
tological examination of major organs was performed 
after the end of treatment and again did not reveal any 
apparent signs of toxicity or differences in mean body 
weights between the respective treatment arms (Fig. 8c). 
Xenograft tumor tissues were harvested at the end of 
treatment for analysis of drug target genes. Western blot 
analyses of excised tumors were found to be in line with 
previous in vitro results and showed decreased phospho-
rylation of I-kappa-B-alpha in both EF24 treatment arms 
(i.e. monotherapy or gemcitabine combination, respec-
tively), while void liposomes or gemcitabine both did not 
show any such effect (Fig. 8d). Used as monotherapeutic 
agent, Lipo-EF24 failed to suppress NF-kappaB activation 
in vivo as observed in western blot analyses of resected 
xenograft tumor tissues. However, in combination with 
gemcitabine significant inhibition of phosphorylation of 
NF-kappaB-p65 and hence inactivation of NF-kappaB 
Fig. 6 Toxicity profile of void liposomes. a The toxicity of void liposomes was examined in ten pancreatic cancer cell lines as well as non-malignant 
HPNE cells. These cells were exposed to increasing doses of void liposomes for 72 h and growth inhibition was determined using MTS assays. b 
The hemolytic activity of void or EF24-loaded liposomes on erythrocytes (RBCs) was evaluated using ex vivo RBC hemolysis assays. c In vivo toxicity 
studies were performed by systemic administration of void liposomes, Lipo-EF24 (both at 10 mg/kg i.v. thrice weekly for a total of 3 weeks) or PBS as 
mock treatment control to CD1 wildtype mice. Body weights in the three respective treatment arms were assessed on a weekly basis and no signifi-
cant differences in mean body weights were observed during the course of experiment. d Histopathological assessment of major organs obtained 
from these mice did not show any discernible abnormalities or other evidence of toxicity. Representative HE sections of major organ sites obtained 
from mice treated with void liposomes (VL) or Lipo-EF24 (EL) are shown
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signaling could be detected even in the in vivo situation 
in resected tumor tissues.
Discussion
Pancreatic cancer is a dismal disease and novel thera-
peutic options are urgently required. The plant alkaloid 
curcumin and active derivatives have recently been iden-
tified as a promising group of novel therapeutic agents 
in pancreatic as well as in others cancers [4, 5, 8]. For 
the parent compound curcumin, there is a large body of 
evidence documenting it’s in  vitro activity against pan-
creatic cancer cells. These studies show that curcumin is 
a highly pleiotropic substance that acts on several onco-
genic key signaling pathways, inluding inflammatory 
cytokines, JAK/STAT and NF-kappaB signaling path-
ways [29, 30]. Nano-encapsulation of curcumin has been 
shown to enable systemic in vivo administration of cur-
cumin while preserving its antineoplastic on-target effi-
cacy by our own group as well as by others [4, 5, 31–33], 
and early clinical evaluation of this concept is currently 
ongoing.
3,5-bis(2-fluorobenzylidene)-4-piperidone (EF24) was 
developed from curcumin as a synthetic monoketone 
compound that exhibited potent anticancer activity 
[8]. Tan et  al. [34] found that EF24 upregulated cellular 
antioxidant responses as observed by the suppression 
of reactive oxygen species, generation and activation of 
antioxidant response element-dependent gene transcrip-
tion in ovarian cancer cells and was more potent than 
curcumin in reducing VEGF secretion.
In hepatocellular carcinoma cells EF24 led to induc-
tion of apoptosis, inhibition of proliferation and G2/M 
cell cycle arrest that were accompanied by blockade of 
NF-kappaB signaling [25]. Moreover, intraperitoneal 
administration of EF24 solubilized using DMSO caused 
significant growth delay of PLC/PRF/5 or Hepa1-6 
xenografts [25, 35]. While this study convincingly dem-
onstrates the in  vivo therapeutic potential of EF24 as 
putative future antineoplastic drug, solubilization in 
DMSO is not a viable concept that could be easily trans-
lated to clinical application in humans due to toxic side 
effects of concentrated DMSO. Therefore, novel ways of 
Fig. 7 In vivo pharmacokinetics of EF24 loaded liposomes. a Graphical representation of the results from LC–MS/MS measurements. Left linear 
scale; right semilogarithmic scale. Plasma concentrations of EF24 were determined at 0.25, 1, 2, 3, 4, 6, 8 and 24 h after intravenous administration 
of liposomal EF24 formulation, given as single dose equivalent to 10 mg/kg EF24. For each time point data from at least two to four mice were 
analysed. b Graphical representation of the results of free (not encapsulated) EF24 solubilized in DMSO from LC–MS/MS measurements. Left linear 
scale; right semilogarithmic scale
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encapsulating EF24 will be required in order to evaluate 
its therapeutic efficacy in humans, and pegylated liposo-
mal nanoparticles have already been proven to be a viable 
option for other agents [9, 10].
Adams et al. [23] suggested that EF24 induces cell-cycle 
arrest in G2/M and redox-mediated induction of apopto-
sis by altering mitochondrial function. In another study 
EF24 was found to inhibit proliferation of cisplatin-resist-
ant ovarian cancer cells by induction of G2/M cell cycle 
arrest and to induce apoptosis by upregulation of mem-
branous FasL and dephosporylation of Akt. In this study, 
EF24 treatment caused phosphorylation and upregula-
tion of PTEN, and siRNA-mediated PTEN-knockdown 
partially rescued induction of apoptosis and cell cycle 
arrest [36]. In line with these previous observations by 
others, this present study shows that in pancreatic cancer 
cells treatment with EF24 leads to inhibition of prolifera-
tion and net cell growth as well as induction of apoptosis.
Moreover, EF24 has previously been identified as 
potent inhibitor of the oncogenic NF-kappaB signal-
ing pathway that directly inhibits the catalytic activity 
of IkappaB kinase (IKK), blocks nuclear translocation of 
NF-kappaB and inhibits tumor necrosis factor (TNF)-
alpha-induced IkappaB phosphorylation and degradation 
[24]. In this study the authors report that EF24 inhibited 
in vitro cell viability of various cancer cell lines (derived 
from lung, breast, ovarian and cervical cancer) with ten 
times higher potency as compared to curcumin. Con-
firming and extending these previous observations by 
others our data presented here show that in pancreatic 
cancer cells EF24 causes potent inhibition of NF-kappaB 
signaling.
Agashe et al. [37] described preparation of a liposomal 
nanoformulation of EF24 that differed from the approach 
chosen in this current study by first generating inclusion 
complexes of EF24 in hydroxypropyl-beta-cyclodextrin 
Fig. 8 In vivo therapeutic effect of Lipo-EF24 on MIAPaCa xenograft tumor growth. a Growth of subcutaneous MIAPaCa xenografts was signifi-
cantly inhibited in nude mice after treatment with Lipo-EF24 and gemcitabine in combination as shown by measured tumor volumes (n = 8) for 
each treatment arm after 3 weeks. Lipo-EF24 or gemcitabine used as single agents did not show any significant effect when compared to void 
liposomes as control. b Tumor weights measured at the end of treatment also showed significant reduction in the combination treatment arm as 
compared to either single agents or void liposomal control. c During the course of treatment, no difference in the mean body weight of mice was 
observed between the respective treatment arms. d Lipo-EF24 in combination with gemcitabine suppressed NF-kappaB activation in MIAPaCa 
xenografts, as demonstrated by marked inhibition of the phosphorylated form of its inhibitor protein I-kappa-B-alpha as well as NF-kappaB-p65, 
determined by western blot analysis of frozen tumor tissues
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(HPβCD), which were then encapsulated into liposomes 
(designated “drug-in-CD-in liposome” approach). The 
liposomal EF24 particles were characterized in vitro and 
were found to inhibit proliferation of H441 lung adeno-
carcinoma as well as PC-3 prostate cancer cells more 
potently than non-encapsulated EF24 at a concentra-
tion of 10 µM. However, in this study in vivo evaluation 
of the synthesized EF24 nanoformulation was limited to 
pharmacokinetics and biodistribution studies in rats, and 
in  vivo efficacy studies using suitable animal models of 
cancer were not carried out.
To the best of our knowledge our current study pre-
sented here is the first report of generation and phys-
ico-chemical characterization of a pegylated liposomal 
nanoformulation of EF24 (Lipo-EF24) for systemic 
administration that includes demonstration of in  vivo 
antitumor efficacy in a murine xenograft model of human 
pancreatic cancer. In line with previous reports cited 
above, Lipo-EF24 led to direct induction of apoptosis as 
demonstrated by means of cleaved PARP and caspase-3 
activity and inhibition of NF-kappaB signaling in pancre-
atic cancer cells. Of note, these molecular mechanisms 
could also be reproduced in  vivo by analyzing Lipo-
EF24-treated xenograft tumor tissues. Another remark-
able finding of our study was the apparent non-toxicity 
of the Lipo-EF24 formulation presented here in murine 
in vivo models, which prompts the possibility of studying 
combination regimens. In fact, in xenograft experiments 
a convincing tumor growth inhibition was not achieved 
by Lipo-EF24 monotherapy but rather by its combination 
with the chemotherapeutic drug gemcitabine.
This observation seems to be in line with another 
recent report convincingly demonstrating that EF24 
acts as strong inhibitor of FANCD2 monoubiquityla-
tion (FANCD2-Ub) and targets the Fanconi Anemia (FA) 
pathway through inhibition of the NF-kappaB path-
way kinase IKK [38]. Based on these observations one 
would infer from other cancer entities that there might 
be therapeutic synergism with other agents that put addi-
tional stress on DNA repair pathways, and in fact the 
authors found ATM-deficient tumor cells to be twofold 
more sensitive to EF24 treatment than matched wild-
type controls; moreover, it was observed that EF24 spe-
cifically sensitized FA-competent cells to mitomycin C, a 
DNA crosslinker previously described to be particularly 
active in cancer cells with defective DNA repair path-
ways, including molecularly defined subsets of pancre-
atic cancer [39]. Based on these promising results it is 
highly tempting to speculate, whether there might also 
be synergism with other DNA-damaging agents such as 
cisplatin or irinotecan or with PARP inhibitors such as 
olaparib, that have also been found to be active in these 
subsets of cancers. Finally, a recent report suggested that 
gastrointestinal cancers including pancreatic cancers 
that are deficient in DNA mismatch-repair might be par-
ticularly vulnerable to therapeutic immune checkpoint 
inhibition by means of PD-1 antibodies [40], and it is 
therefore tempting to speculate whether treatment with 
Lipo-EF24 might likewise sensitize pancreatic cancer 
cells to this currently highly promising novel therapeu-
tic strategy. Future studies examining these approaches 
therefore seem to be of obvious interest.
A recent report on preclinical hepatocellular carci-
noma models suggested that EF24 might be used to 
overcome sorafenib-induced intratumoral hypoxia and 
therapy-resistance by inhibition of hypoxia-inducible 
factor (HIF)-1alpha by cytoplasmic sequestration and 
enhanced degradation [41]. Tumor hypoxia is a feature 
commonly observed in pancreatic cancer and is believed 
to be one of the key factors contributing to the gen-
eral resistance of pancreatic cancer against therapeutic 
intervention. Of interest, another molecularly targeted 
approach to overcome hypoxia-mediated resistance 
against therapeutic intervention in pancreatic cancer has 
recently been suggested by inhibition of aberrant Hedge-
hog signaling, and in fact pharmacological Hedgehog 
inhibition was characterized by marked therapeutic syn-
ergism with administration of gemcitabine in  vivo [19, 
42], similarly to what has been found for Lipo-EF24 in 
this current study.
Another novel therapeutic approach that is currently 
being evaluated in pancreatic cancer is to block pro-
inflammatory signaling pathways by means of small 
molecule inhibitors, promising phase 2 clinical data has 
recently been presented for the Janus Kinase inhibi-
tor ruxolitinib [43, 44], although subsequent phase 3 
data have been sobering. Since EF24 likewise has been 
found to inhibit JAK/STAT signaling and secretion of 
proinflammatory cytokines as well as other inflamma-
tory pathways such as NF-kappaB and due to its appar-
ent non-toxicity, it can be hypothesized that there might 
be therapeutic synergism when combining ruxolitinib 
therapy with Lipo-EF24, and this concept should be 
addressed in subsequent future studies.
Of note, it might be envisioned to co-encapsulate sev-
eral compounds of such combination regimens (e.g. 
EF24 + gemcitabine +  targeted agent) in one liposomal 
nanoparticle in an attempt to further enhance co-deliv-
ery to neoplastic tissues and thus increase therapeutic 
response. Future studies following up on this idea are 
currently already under way in our laboratory.
Conclusions
Taken together the experimental results presented here 
demonstrate that liposomal formulation of EF24 shows 
therapeutic efficacy against pancreatic cancer tumors by 
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suppression of NF-kappaB activation, mainly by inhibit-
ing phosphorylation and subsequent degradation of its 
inhibitor protein I-kappa-B-alpha. Moreover, due to its 
very favorable toxicity profile Lipo-EF24 is also a promis-
ing candidate to further evaluate in combinatorial regi-
mens together with gemcitabine or other targeted agents 
as pointed out above. The clinical value of such combina-
torial approaches should be evaluated in future follow-up 
studies.
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